DDrare: Database of Drug Development for Rare Diseases

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-FDG; 68Ga-FAPI; Abatacept; Afucosylated IgG1 kappa monoclonal antibody; Belimumab; Corticosteroids; Device: Mayo Interactive Breath Hold Monitor; Drug free, IS monotherapy and GC combined with IS; Extra blood draw samples; Glucocorticoids; INEBILIZUMAB; Inebilizumab; Leflunomide; Lenalidomide; MONITOR; Methionine; Mycophenolate; Mycophenolate mofetil; Perflubutane; Prednisolone; Prednisone; Prednisone and Belimumab; Prednisone and Mycophenolate mofetil; Procedure: biliary stent; Rilzabrutinib; Rituximab; T 614; Thalidomide; XMAB5871; XmAb5871; Zanubrutinib; Zanubrutinib 80 MG; [XmAb5871]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02705638 (ClinicalTrials.gov)	April 2016	7/3/2016	Treatment of IgG4-Related Disease With Revlimid and Rituximab	Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial	Immunoglobulin G Subclass 4 Related Disease;IgG4-related Disease;Autoimmune Pancreatitis;IgG4-related Sclerosing Cholangitis;Retroperitoneal Fibrosis	Drug: Rituximab;Drug: Lenalidomide	Mayo Clinic	Celgene Corporation	Completed	18 Years	N/A	All	6	Phase 1	United States
2	NCT01584388 (ClinicalTrials.gov)	April 2012	22/4/2012	Rituximab in IgG4-RD: A Phase 1-2 Trial	Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial	Retroperitoneal Fibrosis;Autoimmune Pancreatitis;Sialadenitis;Pseudotumor	Drug: Rituximab	Massachusetts General Hospital	Genentech, Inc.	Completed	18 Years	N/A	All	30	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02705638
(ClinicalTrials.gov)

April 2016

7/3/2016

Treatment of IgG4-Related Disease With Revlimid and Rituximab

Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial

Immunoglobulin G Subclass 4 Related Disease;IgG4-related Disease;Autoimmune Pancreatitis;IgG4-related Sclerosing Cholangitis;Retroperitoneal Fibrosis

Drug: Rituximab;Drug: Lenalidomide

Mayo Clinic

Celgene Corporation

Completed

18 Years

N/A

All

Phase 1

United States

NCT01584388
(ClinicalTrials.gov)

April 2012

22/4/2012

Rituximab in IgG4-RD: A Phase 1-2 Trial

Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial

Retroperitoneal Fibrosis;Autoimmune Pancreatitis;Sialadenitis;Pseudotumor

Drug: Rituximab

Massachusetts General Hospital

Genentech, Inc.

Completed

18 Years

N/A

All

Phase 1;Phase 2

United States